HER2, HER3, and TROP2: Diagnostic Testing and Treatment Implications in Breast, GI, and Lung Cancers

Review the latest expert guidance on assessing and targeting HER2, HER3, and TROP2 in the metastatic setting for diverse malignancies with on-demand Webcasts and downloadable slides from CCO’s live Webinars, along with expert-authored commentaries, a pocket guide on best practices for testing, and brief Medical Minute slide/audio presentations for oncologists and pathologists.
Mark D. Pegram, MD
Program Director
Sandip P. Patel, MD

ClinicalThought

What is new in testing for HER2 in breast cancer and beyond? How might newly approved and emerging therapies targeting HER2, HER3, and TROP2 affect your practice? Here’s my take.

Mark D. Pegram, MD
Program Director
Released: July 23, 2020

How could emerging therapies targeting HER2, HER3, and TROP2 affect management of patients with NSCLC? Here are my thoughts on promising agents and potential clinical implications.

Sandip P. Patel, MD Released: November 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue